- ￥4500
- Sino Biological
- 40592-V08H121
- 2026年01月26日
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 规格：
100 µg
重组新冠病毒 B.1.1.529 (Omicron) Spike RBD 蛋白 (His标签)（产品说明）
蛋白名称：SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)
蛋白构建：A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa.
表达宿主：HEK293 Cells
蛋白纯度：> 95 % as determined by SDS-PAGE. > 95 % as determined by SEC-HPLC.
蛋白活性：Immobilized human ACE2 protein (mFc tag)(Cat: 10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)(Cat: 40592-V08H121), the EC50 is 3-10 ng/mL.
蛋白内毒素：< 1.0 EU per μg protein as determined by the LAL method.
预测N端：Arg 319
蛋白分子量：The recombinant SARS-CoV-2 Spike RBD consists of 234 amino acids and predicts a molecular mass of 26.83 kDa.
蛋白NP号：YP_009724390.1
蛋白氨基酸序列：Arg319-Phe541
蛋白标签：C-His
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
蛋白名称：SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)
蛋白构建：A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa.
表达宿主：HEK293 Cells
蛋白纯度：> 95 % as determined by SDS-PAGE. > 95 % as determined by SEC-HPLC.
蛋白活性：Immobilized human ACE2 protein (mFc tag)(Cat: 10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)(Cat: 40592-V08H121), the EC50 is 3-10 ng/mL.
蛋白内毒素：< 1.0 EU per μg protein as determined by the LAL method.
预测N端：Arg 319
蛋白分子量：The recombinant SARS-CoV-2 Spike RBD consists of 234 amino acids and predicts a molecular mass of 26.83 kDa.
蛋白NP号：YP_009724390.1
蛋白氨基酸序列：Arg319-Phe541
蛋白标签：C-His
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验该产品被引用文献
1, Li Y, et al. Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants.iScience, PubMed ID: 35607524
2, Wang S, et al. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.Cell reports, PubMed ID: 35594869
3, Chen C, et al. Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains.iScience, PubMed ID: 35875685
4, Emmenegger M, et al. Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants.iScience, PubMed ID: 35875683
5, Hawman DW, et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.EBioMedicine, PubMed ID: 35932641
6, Forte E, et al. Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS.Journal of proteome research, PubMed ID: 36343328
7, Saville JW, et al. Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein.Cell reports, PubMed ID: 36640338
8, Song Z, et al. Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology.Vaccines, PubMed ID: 36851319
9, Emmenegger M, et al. Protocol to determine antibody affinity and concentration in complex solutions using microfluidic antibody affinity profiling.STAR protocols, PubMed ID: 36853663
10, Carlson EC, et al. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline.International journal of molecular sciences, PubMed ID: 36982671
11, Verstraete MM, et al. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.mAbs, PubMed ID: 37229608
12, Wang Y, et al. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.Nature communications, PubMed ID: 38287016
13, Yang M, et al. Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity.Signal transduction and targeted therapy, PubMed ID: 38355661
14, Poulakou G, et al. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Frontiers in immunology, PubMed ID: 38694503
15, Park S, et al. An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation.Nature communications, PubMed ID: 38643233
16, Chiu CT, et al. An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.International journal of nanomedicine, PubMed ID: 39050877
17, García-Silva I, et al. Synthesis and Characterization of Thiolated Nanoparticles Based on Poly (Acrylic Acid) and Algal Cell Wall Biopolymers for the Delivery of the Receptor Binding Domain from SARS-CoV-2.Pharmaceutics, PubMed ID: 39065588
2, Wang S, et al. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.Cell reports, PubMed ID: 35594869
3, Chen C, et al. Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains.iScience, PubMed ID: 35875685
4, Emmenegger M, et al. Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants.iScience, PubMed ID: 35875683
5, Hawman DW, et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.EBioMedicine, PubMed ID: 35932641
6, Forte E, et al. Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS.Journal of proteome research, PubMed ID: 36343328
7, Saville JW, et al. Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein.Cell reports, PubMed ID: 36640338
8, Song Z, et al. Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology.Vaccines, PubMed ID: 36851319
9, Emmenegger M, et al. Protocol to determine antibody affinity and concentration in complex solutions using microfluidic antibody affinity profiling.STAR protocols, PubMed ID: 36853663
10, Carlson EC, et al. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline.International journal of molecular sciences, PubMed ID: 36982671
11, Verstraete MM, et al. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.mAbs, PubMed ID: 37229608
12, Wang Y, et al. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.Nature communications, PubMed ID: 38287016
13, Yang M, et al. Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity.Signal transduction and targeted therapy, PubMed ID: 38355661
14, Poulakou G, et al. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Frontiers in immunology, PubMed ID: 38694503
15, Park S, et al. An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation.Nature communications, PubMed ID: 38643233
16, Chiu CT, et al. An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.International journal of nanomedicine, PubMed ID: 39050877
17, García-Silva I, et al. Synthesis and Characterization of Thiolated Nanoparticles Based on Poly (Acrylic Acid) and Algal Cell Wall Biopolymers for the Delivery of the Receptor Binding Domain from SARS-CoV-2.Pharmaceutics, PubMed ID: 39065588
相关实验
His 标签蛋白纯化效果不理想，宝宝心里苦呀。今天，小编来跟大家一起找找原因。 纯化所得组分中没有收集到重组的His标签蛋白。该问题主要可以分为以下两个方面： 1、His标签蛋白没有结合到填料上就流穿了 原因一 超声的功率不对。超声功率过高，容易导致蛋白炭化；功率过低，蛋白释放不出来。 建议 改变超声功率，同时可以在超声前加入溶菌酶。 原因二 结合缓冲液条件不合适。 建议 检查结合缓冲液中是否有影响结合的因素，如：金属离子螯合剂、强还原剂、过高的咪唑浓度。同时，优化缓冲液的pH、盐
日前，北京大学生命科学学院魏文胜课题组在 Cell 杂志上在线发表题为“Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants”的研究论文。 魏文胜团队首先建立了体外高效制备高纯度环状 RNA 的技术平台，针对新型冠状病毒及其变异株，设计了编码新冠病毒刺突蛋白（Spike）受体结构域（RBD）的环状 RNA 疫苗。 该项研究中制备的针对新冠病毒德尔塔变异株的环状 RNA 疫苗（circRNARBD
高福院士团队 Lancet 发文：北京 COVID-19 病例分析表明，疫情爆发期间未出现新变种
导读 COVID-19 大流行已经持续了近 3 年，目前仍然是一个全球关注的热点话题。鉴于新冠病毒的广泛传播和不断演变，全球出现了众多变种，比如 alpha (B.1.1.7)、beta (B.1.351)、gamma (P.1)、delta (B.1.617.2)、omicron (B.1.1.529) 等。其中，Omicron 最早在南非被发现，增加的高传播力使其迅速成为全球范围内的优势毒株。 2022 年 12 月之前，中国采取了与其他国家不同的应对策略，从 2020 年的武汉封
技术资料暂无技术资料 索取技术资料
文献支持
重组SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD蛋白 (His标签)
￥4500
